Overactive Bladder – Drugs In Development, 2024
Powered by ![]()
Unlock hidden opportunities in the Pharmaceuticals industry
Empower your strategies with our Overactive Bladder – Drugs In Development, 2024 report and make more profitable business decisions.
Overactive bladder is a problem with bladder-storage function that causes a sudden urge to urinate. The urge may be difficult to stop, and overactive bladder may lead to the involuntary loss of urine (incontinence). Symptoms include feeling a sudden urge to urinate that’s difficult to control, experiencing urge incontinence, and awakening two or more times in the night to urinate. Treatment includes changes in lifestyle, and medications that relax the bladder can be effective for relieving symptoms of overactive bladder and reducing episodes of urge incontinence.
The Overactive Bladder drugs in development market research report provide comprehensive information on the therapeutics under development for Overactive Bladder, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action and product description of the therapeutics, and the latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Overactive Bladder and features dormant and discontinued products.
Note:
* This is an “on-demand” report and will be delivered within 2 business days (excluding weekends and holidays) of the purchase.
* Certain sections in the report may be removed or altered based on the availability and relevance of data.
| Quick View – Overactive Bladder | Key Targets |
|
|
| Key Mechanisms of Action |
|
||
| Key Routes of Administration |
|
||
| Key Molecule Types |
|
||
| Major Companies |
|
||
Scope
- Therapeutics in Development: Covering 30 molecules, with 29 developed by companies and the rest by universities/institutes.
- Analysis Parameters: Offering insights by stage of development, drug target, MoA, RoA, and molecule type for a comprehensive overview.
- Pharmacological Insights: Understand the descriptive pharmacological action of therapeutics.
- Development History: Access the complete research and development history.
- Latest News and Press Releases: Stay updated with the latest developments through comprehensive news coverage.
Reasons to Buy
- Holistic insights: Understand the broad spectrum of Overactive Bladder therapeutics, aiding strategic decision-making with insights into stages, targets, MoA, RoA and molecule types.
- Pipeline Exploration: Explore the detailed Overactive Bladder pipeline, offering nuanced analysis of drug targets, mechanisms of action and routes of administration for varied decision-making.
- Comprehensive R&D: Access thorough R&D histories, providing a comprehensive understanding of Overactive Bladder treatments for adaptable decision-making.
- Save valuable hours: Identify key players steering innovation in therapeutics, enabling strategic partnerships.
Key Players
Aardvark Therapeutics IncAetas Pharma Co Ltd
Bio-Fd&C Co Ltd
Cisen Pharmaceutical Co Ltd
DelNova Inc
Dompe Farmaceutici SpA
Dong-A ST Co Ltd
DongKoo Bio & Pharma Co Ltd
Exxel Pharma Inc
Forcyte Biotechnologies Inc
Hanmi Pharmaceuticals Co Ltd
Hetero Drugs Ltd
Imbrium Therapeutics LP
Jeil Pharmaceutical Co Ltd
Kissei Pharmaceutical Co Ltd
Korea United Pharm Inc
Lipella Pharmaceuticals Inc
Lotus Pharmaceutical Co Ltd
Merck & Co Inc
Pantherics Inc
PeLeMed Co Ltd
Pharmacorex Co Ltd
Profem GmbH
R-Pharm
Sea4Us - Biotecnologia e Recursos Marinhos Lda
Sumitomo Pharma Co Ltd
Taiho Pharmaceutical Co Ltd
Therapeutic Systems Research Laboratories Inc
University of Vermont
Urovant Sciences Inc
Viatris Inc
Xuanzhu Biotechnology Co Ltd
Table of Contents
Table
Figures
Frequently asked questions
Related reports
View more Overactive Bladder reports